New Cancer Drug Could Lower Progression Risk
A new bispecific antibody therapy shows promise for cancer patients in recent clinical trial results.
Updated on Oct. 28, 2026 in Cancer
AbbVie has submitted an application to the FDA for review of etentamig, an experimental cancer treatment. The filing follows trial results showing the drug could improve response rates for patients compared to current standard care.
Why it matters
The submission represents a milestone for this investigational therapy, which aims to provide a new treatment option by potentially slowing disease progression for patients who have limited alternatives.
In a Phase 3 trial of 393 patients, the investigational drug etentamig achieved a 74.0% overall response rate compared to 45.7% for those receiving standard therapy. Participants in the etentamig group experienced a 60% lower hazard of progression or death over the study period.
The players
AbbVie
A global biopharmaceutical company focused on developing therapies for oncology, immunology, and neuroscience.
The details
Etentamig is an intravenous bispecific antibody designed to target specific cells. In the CERVINO trial, patients were assigned via 1:1 randomization to receive either the new drug or standard treatment. The regimen involves an initial step-up dose followed by monthly administrations to manage the therapeutic response.
Timeline
October 27, 2026: AbbVie filed a biologics license application for FDA review.
Health Landscape
The filing of this application moves etentamig into the formal FDA regulatory review pipeline. It sits among a growing class of bispecific antibodies being studied as alternatives to traditional standard-of-care treatments for patients with advanced disease.
As etentamig remains an investigational therapy, it is not currently available for clinical use. Patients interested in how this trial outcome might eventually impact their treatment options should discuss the latest research updates with their oncologist.
The takeaway
The clinical trial results for etentamig suggest a potential improvement in response rates compared to standard therapy. Patients should continue to monitor their current treatment plans with their medical team and stay informed about future regulatory milestones for emerging immunotherapy options.
Further reading
For more on current developments in oncology, visit our Cancer section.
